Redmile Group’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-885,927
| Closed | -$30M | – | 36 |
|
|
2025
Q4 | $30M | Buy |
885,927
+333,333
| +60% | +$10.4M | 2.21% | 12 |
|
|
2025
Q3 | $14.3M | Sell |
552,594
-78,092
| -12% | -$1.02M | 1.39% | 19 |
|
|
2025
Q2 | $5.05M | Sell |
630,686
-178,729
| -22% | -$1.36M | 0.54% | 34 |
|
|
2025
Q1 | $7.9M | Hold |
809,415
| – | – | 0.75% | 28 |
|
|
2024
Q4 | $10.2M | Buy |
809,415
+746,348
| +1,183% | +$9.48M | 0.71% | 32 |
|
|
2024
Q3 | $1.01M | Sell |
63,067
-4,018
| -6% | -$81.3K | 0.06% | 61 |
|
|
2024
Q2 | $1.64M | Sell |
67,085
-15,715
| -19% | -$726K | 0.1% | 57 |
|
|
2024
Q1 | $5.95M | Buy |
82,800
+36,953
| +81% | +$5.14M | 0.22% | 67 |
|
|
2023
Q4 | $9.11M | Sell |
45,847
-7,589
| -14% | -$939K | 0.33% | 53 |
|
|
2023
Q3 | $7.1M | Sell |
53,436
-554
| -1% | -$90.4K | 0.34% | 50 |
|
|
2023
Q2 | $8.08M | Sell |
53,990
-32,027
| -37% | -$4.99M | 0.31% | 52 |
|
|
2023
Q1 | $12.6M | Sell |
86,017
-12,087
| -12% | -$2.44M | 0.55% | 51 |
|
|
2022
Q4 | $15.5M | Hold |
98,104
| – | – | 0.64% | 42 |
|
|
2022
Q3 | $18.9M | Sell |
98,104
-4,125
| -4% | -$780K | 0.73% | 40 |
|
|
2022
Q2 | $14.9M | Buy |
102,229
+8,644
| +9% | +$1.15M | 0.57% | 43 |
|
|
2022
Q1 | $16.5M | Buy |
+93,585
| New | +$17.7M | 0.51% | 47 |
|
Redmile Group's RAPT Position: Q1 2026 in Review
Redmile Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 885,927 shares — an estimated $30M sold.
Redmile Group first reported a position in RAPT in Q1 2022 and held it in 16 quarters. The position peaked at $30M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Redmile Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Redmile Group sold 885,927 RAPT Therapeutics shares in Q1 2026, an estimated $30M.
- Redmile Group first reported a position in RAPT Therapeutics in Q1 2022 and held it in 16 quarters.
- Redmile Group's RAPT Therapeutics position peaked at $30M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.